Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma

Fineline Cube Dec 23, 2025
Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Fineline Cube Dec 23, 2025
Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Policy / Regulatory

NMPA Issues Internet Pharma Info Rules Requiring Record-Filing Display

Fineline Cube Dec 23, 2025
Company Drug

Novo Nordisk’s Wegovy Wins China Cardiovascular Approval in Weight-Loss Market Expansion

Fineline Cube Dec 23, 2025
Company Drug

Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections

Fineline Cube Dec 23, 2025
Company Drug

BeiGene’s Brukinsa Receives EC Approval for CLL Treatment

Fineline Cube Nov 18, 2022

China-based biotech BeiGene Ltd. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced receiving marketing approval...

Company

Zhangjiang AI New Drug R&D Alliance Expands with New Members

Fineline Cube Nov 18, 2022

The Zhangjiang AI New Drug R&D Alliance has welcomed new participants, including Regor Therapeutics, Roche,...

Company Deals

Subtle Medical Secures Series B Funding for AI-Powered Medical Imaging

Fineline Cube Nov 17, 2022

Subtle Medical, an Artificial Intelligence (AI)-empowered medical imaging company based in Guangdong, has reportedly raised...

Company Drug

Hengrui Pharmaceuticals Receives Clinical Trial Approvals for Three New Drugs

Fineline Cube Nov 17, 2022

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving clinical trial approvals for three in-house...

Company Deals

Rainsure Scientific Secures Series C1 Funding for Digital PCR Development

Fineline Cube Nov 17, 2022

Rainsure Scientific, a Suzhou-based developer of digital PCR instruments and RUO detection kits, has reportedly...

Company Drug

CSPC Pharma’s rhTNK-tPA Accepted for Review by NMPA for Stroke Indication

Fineline Cube Nov 17, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that a supplementary market filing for...

Company Deals

Asia Pacific Medical Group Secures Series A Funding for Hospital Expansion

Fineline Cube Nov 17, 2022

Private healthcare group Asia Pacific Medical Group (APMG) has raised “hundreds of millions” of renminbi...

Company Drug

Haisco’s HSK31858 Gains Ethical Approval for Phase II Study in NCFBE

Fineline Cube Nov 17, 2022

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its drug candidate HSK31858...

Company Drug

CANbridge’s CAN106 Receives Orphan Drug Designation for Myasthenia Gravis

Fineline Cube Nov 17, 2022

China-based rare disease firm CANbridge Pharmaceuticals Inc. (HKG: 1228) has announced receiving Orphan Drug Designation...

Company Deals

HitGen Partners with Guangzhou AIChemEco for Automated Synthesis Technology

Fineline Cube Nov 17, 2022

China-based HitGen Inc. (SHA: 688222) has announced a partnership with compatriot firm Guangzhou AIChemEco. The...

Company

Harbour BioMed Establishes Nona Biosciences for Next-Generation Antibody Development

Fineline Cube Nov 17, 2022

Harbour BioMed (HKG: 2142), a biotech company with operations in the Netherlands, the United States,...

Company

Novartis Considers Sale of Non-Core Units to Fund Innovation

Fineline Cube Nov 17, 2022

Swiss pharmaceutical giant Novartis AG (NYSE: NVS) is reportedly considering the sale of certain ‘non-core’...

Company Deals

Sequanta Technologies Partners with Illumina to Introduce NovaSeq X Series

Fineline Cube Nov 17, 2022

Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, has entered into...

Company Drug

Ascletis Pharma’s PD-L1 Inhibitor ASC61 Gains NMPA IND Approval

Fineline Cube Nov 17, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) has announced the approval of the Investigational New Drug...

Company Deals

MicroTech Medical Plans IPO on Shanghai’s STAR Market

Fineline Cube Nov 17, 2022

China-based diabetes specialist MicroTech Medical (Hangzhou) Co., Ltd (HKG: 2235) has announced plans to conduct...

Drug

Kelun Pharma’s SKB264 Advances to Phase II Study for NSCLC

Fineline Cube Nov 16, 2022

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that its antibody drug conjugate...

Company

Gracell’s FasTCAR Platform Wins Fierce Life Sciences Innovation Award

Fineline Cube Nov 16, 2022

China-based Gracell Biotechnologies Inc’s (Nasdaq.GRCL) FasTCAR technology platform has been named the winner of this...

Company Deals

Walvax Biotechnology Expands Manufacturing Partnership with Etana for PCV and HPV Vaccines

Fineline Cube Nov 16, 2022

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has entered into another manufacturing cooperation agreement with...

Company Deals

Simcere Pharmaceuticals Licenses Idorsia’s Insomnia Therapy Daridorexant for Greater China

Fineline Cube Nov 16, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the establishment of a licensing agreement with...

Company

Sirnaomics Announces Key Executive Promotions Effective November 15

Fineline Cube Nov 16, 2022

Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced key changes to its C-suite,...

Posts pagination

1 … 534 535 536 … 601

Recent updates

  • NMPA Issues Internet Pharma Info Rules Requiring Record-Filing Display
  • Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma
  • Novo Nordisk’s Wegovy Wins China Cardiovascular Approval in Weight-Loss Market Expansion
  • Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections
  • Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA Issues Internet Pharma Info Rules Requiring Record-Filing Display

Company Deals

Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma

Company Drug

Novo Nordisk’s Wegovy Wins China Cardiovascular Approval in Weight-Loss Market Expansion

Company Drug

Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.